|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Dulak, AM, Stojanov, P, Peng, S, Lawrence, MS, Fox, C, Stewart, C, Bandla, S, Imamura, Y, Schumacher, SE, Shefler, E, McKenna, A, Carter, SL, Cibulskis, K, Sivachenko, A, Saksena, G, Voet, D, Ramos, AH, Auclair, D, Thompson, K, Sougnez, C, Onofrio, RC, Guiducci, C, Beroukhim, R, Zhou, Z, Lin, L, Lin, J, Reddy, R, Chang, A, Landrenau, R, Pennathur, A, Ogino, S, Luketich, JD, Golub, TR, Gabriel, SB, Lander, ES, Beer, DG, Godfrey, TE, Getz, G, Bass, AJ|
The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ∼15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.